REACTIVE CARBONYL SPECIES AND CEREBRAL MICROVASCULAR DISEASES

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 糖尿病（DM）患者患有脑微血管疾病，包括缺血性和腔隙性中风，其发病率比普通人群高3至5倍。在这些个体中，梗塞后的脑损伤程度也加重。更令人不安的是，观察到血糖控制严格的糖尿病患者仍然会出现认知障碍，并且患自发性阿尔茨海默病的风险更高。最近的研究表明，这些缺陷部分源于血脑屏障（BBB）通透性的增加。仍然难以捉摸的是负责启动BBB破坏的分子触发因素。从我们的实验室以及其他一些实验室中出现的令人兴奋的新数据表明，糖尿病期间产生的反应性羰基物质（RCS）可能是这些触发因素之一。我们的工作假设是“糖尿病期间产生的RCS与内皮细胞相互作用并损害其功能，导致血管通透性增加，增加神经系统疾病的发病率。“我们将使用体外研究来阐明RCS损害脑内皮细胞功能的机制，并使用体内研究来表明RCS的慢性升高导致血脑屏障破坏和脑动脉闭塞后脑损伤的增加。本研究将为“RCS-ROC耦合”的概念提供数据支持。“它还将提供关于这组未充分研究的细胞氧化剂如何损害内皮细胞功能导致BBB渗透性增加的机制见解，这是R 01应用方向的基础。从全球范围来看，拟议研究的数据也可能有助于开发新的治疗策略以减缓进展 提高糖尿病患者的生活质量，控制糖尿病并发心血管疾病的发生。 糖尿病护理的经济成本不断上升，估计每年超过1320亿美元。 该项目的具体目标是： 1.目的：探讨丙酮醛（MGO）引起脑内皮细胞（BEC）活性氧增加和功能障碍的机制。 2. 描述MGO循环水平慢性升高对体内内皮细胞功能和BBB通透性的影响，并确定MGO治疗大鼠大脑中动脉闭塞（MCAO）后脑损伤的程度。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Individuals with diabetes mellitus (DM) have cerebral microvascular diseases including ischemic and lacunar strokes at rates three to five times higher than that of the general population. The extent of brain damage following an infarct is also aggravated in these individuals. Even more troubling, are the observations that diabetic patients who have tight blood glucose control still develop cognitive impairment and are at a higher risk of developing spontaneous Alzheimer's disease. Recent studies suggest that these defects stem in part from an increase in blood-brain-barrier (BBB) permeability. What remain elusive are the molecular triggers responsible for initiating BBB breach. Exciting new data emerging from our laboratory as well as a few others indicate that reactive carbonyl species (RCS) generated during diabetes may be one of these triggers. Our working hypothesis is that "RCS generated during diabetes interact with and compromise the function of endothelial cells resulting in vascular permeability, increasing the incidence of neurological disorders." We will use in vitro studies to elucidate mechanisms by which RCS compromise brain endothelial cell function and in vivo studies to show that chronic elevation of RCS leads to blood brain barrier breach and an increase in cerebral damage following cerebral artery occlusion. The proposed research will provide data in support of the concept of "RCS-ROC coupling." It will also provide mechanistic insights into how this group of understudied cellular oxidants impairs endothelial cell function leading to increased BBB permeability, the basis for a direction of an R01 application. More globally, data from the proposed research could also be useful for developing newer therapeutic strategies to slow the progression of cardiovascular diseases during diabetes, improve the quality of life of diabetic patients and control the escalating economic cost of diabetes care, which is estimated to be in excess of $132 billion annually. The specific aims of the project are: 1. To elucidate mechanisms by which methylglyoxal (MGO) increases in reactive oxygen species and dysfunction of brain endothelial cells (BEC). 2. To characterize the effects of chronic elevation of circulating levels of MGO on endothelial cell function and BBB permeability in vivo, and to determine the extent of brain damage following mid cerebral artery occlusion (MCAO) in MGO-treated rats.